|
|
|
| Trends in incidence and mortality of thyroid cancer in Nantong City from 2013 to 2022 |
| HAN Yarong, HAN Yingying, CAI Bo, LIN Ling
|
| Nantong Center for Disease Control and Prevention, Nantong, Jiangsu 226007, China |
|
|
|
|
Abstract Objective To investigate the trends in incidence and mortality of thyroid cancer in Nantong City, Jiangsu Province from 2013 to 2022, so as to provide a basis for optimizing comprehensive regional prevention and control strategies. Methods Data on incidence and mortality of thyroid cancer in Nantong City from 2013 to 2022 were collected via the Nantong Cancer Registration Reporting System. Crude incidence and mortality were calculated. The Chinese population-standardized incidence and Chinese population-standardized mortality were calculated using the standard age structure from the Fifth National Population Census in 2000. The average annual percent change (AAPC) was used to analyze the trends in incidence and mortality of thyroid cancer across different genders, age groups, and urban-rural areas from 2013 to 2022. Results The crude incidence and Chinese population-standardized incidence in Nantong City rose from 5.79/105 and 4.36/105 in 2013 to 34.87/105 and 30.40/105 in 2022, respectively (AAPC=22.226%, 24.139%, both P<0.05). The crude mortality increased from 0.39/105 to 1.07/105 (AAPC=10.469%, P<0.05), while the trend for Chinese population-standardized mortality was not statistically significant (P>0.05). The Chinese population-standardized incidence and Chinese population-standardized mortality for females were 20.41/105 and 0.30/105, respectively, which were 3.28 times and 1.50 times those of males. The Chinese population-standardized incidence showed upward trends for both males and females (AAPC=22.840%, 24.592%, both P<0.05), while the trends for Chinese population-standardized mortality were not statistically significant (both P>0.05). From 2013 to 2022, the crude incidence in the age groups of 15-<45, 45-<65, and 65-<85 years, and the crude mortality in the age group of 65-<85 years showed upward trends (AAPC=27.808%, 21.756%, 13.365%, and 8.030%, all P<0.05), while trends in other age groups were not statistically significant (all P>0.05). The Chinese population-standardized incidence in urban areas was 16.96/105, which was 1.40 times that of rural areas. The Chinese population-standardized mortality in rural areas was 0.27/105, which was 1.29 times that of urban areas. From 2013 to 2022, the Chinese population-standardized incidence in both urban and rural areas and Chinese population-standardized mortality in rural areas showed upward trends (AAPC=17.264%, 27.758%, 6.387%, all P<0.05), while trend in Chinese population-standardized mortality in urban areas was not statistically significant (P>0.05). Conclusions From 2013 to 2022, the crude incidence, Chinese population-standardized incidence, and crude mortality of thyroid cancer in Nantong City all showed upward trends in the total population, males, and females, while the trend in Chinese population-standardized mortality was stable. There were differences in mortality trends between urban and rural areas: the trend in urban areas was stable, whereas the trend in rural areas was upward.
|
|
Received: 08 September 2025
Revised: 28 December 2025
Published: 26 January 2026
|
|
|
|
|
|
[1] 阿迪拉·苏力旦,夏依达·乌斯满江,沙吾拉西·热加甫,等.2020年新疆肿瘤登记地区甲状腺癌流行特征及2016—2020年变化趋势分析[J].预防医学,2025,37(10):1020-1023,1028.
[2] PIZZATO M,LI M M,VIGNAT J,et al.The epidemiological landscape of thyroid cancer worldwide:GLOBOCAN estimates for incidence and mortality rates in 2020[J].Lancet Diabetes Endocrinol,2022,10(4):264-272.
[3] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
[4] 韩仁强,缪伟刚,俞浩,等.2020年江苏省恶性肿瘤发病和死亡现状分析[J].江苏预防医学,2024,35(5):568-574.
[5] 中国疾病预防控制中心.全国慢性病与营养监测技术方案(2023年版)[Z].北京:中国疾病预防控制中心,2023.
[6] 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
[7] 朱宝立,周金意,韩仁强,等.江苏省恶性肿瘤报告(2022)[M].南京:东南大学出版社,2024.
[8] 戴丹,徐伟,吕逸丽,等.2010—2019年安徽省肿瘤登记地区甲状腺癌发病趋势分析[J].中国肿瘤,2024,33(10):849-853.
[9] 项彩英,陈颖,汪德兵,等.2021年浙江省肿瘤登记地区甲状腺癌发病与死亡特征及2000—2021年变化趋势分析[J].中国肿瘤,2025,34(10):756-763.
[10] 谢栋臣,张莉,何纳,等.上海浦东新区九种筛检癌症发病率与死亡率变化模式及过度诊断分析[J].中华肿瘤防治杂志,2025,32(10):599-607.
[11] 严俊涛,魏艳,杨毅,等.国内外过度诊断相关研究的现状及热点分析[J].医学与社会,2023,36(12):1-6.
[12] 张芷悦,何慧婧,单广良,等.甲状腺癌的流行病学现状及其影响因素研究进展[J].中国癌症杂志,2025,35(1):21-29.
[13] 杨志杰,王璐,钱云,等.2009—2019年江苏省肿瘤登记地区甲状腺癌发病趋势和年龄变化特征分析[J].中国肿瘤,2024,33(12):991-998.
[14] 裘凤黔,杜娟,纪云芳,等.2002—2017年黄浦区甲状腺癌发病趋势[J].预防医学,2022,34(1):83-86.
[15] LIU J,XU T M,MA L,et al.Signal pathway of estrogen and estrogen receptor in the development of thyroid cancer[J/OL].Front Oncol,2021,28(11)[2025-12-28].https://doi.org/10.3389/fonc.2021.593479.
[16] 李佳佳,张小鹏,张俊青,等.2021年安徽省合肥市甲状腺癌流行特征及2013—2021年变化趋势分析[J].中国肿瘤,2025,34(3):188-194.
[17] 仇化微,梁天孚,黄苗苗,等.基于年龄-时期-队列模型的中国甲状腺癌发病死亡趋势分析[J].环境卫生学杂志,2023,13(4):270-274.
[18] 王杨凤,刘君.2016—2020年涪陵区甲状腺癌发病趋势[J].预防医学,2022,34(5):511-514.
[19] 董建梅,李伟伟,马昭君,等.2008—2020年江苏省连云港市甲状腺癌发病趋势及年龄变化特征[J/OL].肿瘤学杂志,2015.[2025-12-28].https://link.cnki.net/urlid/33.1266.R.20250627.0841.002.
[20] 成姝雯,董婷,张新,等.2021年四川省肿瘤登记地区恶性肿瘤发病和死亡特征分析[J].预防医学,2025,37(10):1002-1008. |
|
|
|
